Simcere Pharmaceutical Group Limited (FRA:S2P)

Market Cap	3.99B
Revenue (ttm)	844.70M
Net Income (ttm)	104.62M
Shares Out	n/a
EPS (ttm)	0.04
PE Ratio	38.17
Forward PE	26.38
Dividend	0.02 (1.33%)
Ex-Dividend Date	Jun 18, 2025

Volume	n/a
Average Volume	n/a
Open	1.450
Previous Close	1.470
Day's Range	1.450 - 1.450
52-Week Range	0.800 - 1.600
Beta	n/a
RSI	52.67
Earnings Date	Nov 14, 2025

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S2P

Financial Performance

In 2024, FRA:S2P's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY